• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

    2.305 -0.135 (-5.53%)
    Streaming Delayed Price Updated: 12:07 PM EDT, Sep 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fate Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
    Issued on behalf of Avant Technologies Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares... 
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    News headline image
    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Present at Upcoming Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗
    Fate Therapeutics (NASDAQ:FATE) reported mixed Q2 2025 results, beating revenue estimates with $1.9M but posting a $0.29 loss per share. Progress in autoimmune and solid tumor therapies boosted... 
    Via Chartmill
    News headline image
    Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
    Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) 
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4 Analysts Assess Fate Therapeutics: What You Need To Know ↗
     
    Via Benzinga
    News headline image
    Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
    Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications 
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gapping stocks in Monday's session ↗
    There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
    Via Chartmill
    News headline image
    Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic ↗
    CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus. 
    Via Stocktwits
    News headline image
    Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.